A controlled trial of antidepressants in patients with Parkinson disease and depression
Pourquoi ce travail est-il dans la base ?
Une base qui oublie comment elle a trouvé un travail ne peut pas être vérifiée. Voici les voies qui ont admis celui-ci.
Aucune affiliation canadienne. Une base fondée sur la seule affiliation (le devis habituel) n'aurait jamais vu ce travail. C'est l'un des travaux qui justifient l'inversion de la base.
Scores machine (provisoires)
Scores de référence d'un modèle non mature (critères de maturité non atteints, 7 itérations). Un score ordonne; il n'affirme jamais une catégorie.
Les deux têtes enseignantes du modèle étudiant, lues sur ce travail. Un score ordonne la base pour la relecture; il n'affirme jamais une catégorie, et le statut de validation accompagne chaque rangée tel quel.
- Écart entre enseignants
- 0,226 · la distance entre les deux têtes enseignantes sur ce seul travail
- Statut de validation
score_only:v0-immature-baseline· tel quel depuis la passe de notation : score_only signifie que le nombre peut ordonner les travaux, et qu'aucune étiquette de catégorie n'en découle
Résumé
<b>Background:</b> Parkinson disease (PD) is a common neurodegenerative disease affecting up to 1 million individuals in the United States. Depression affects up to 50% of these patients and is associated with a variety of poor outcomes for patients and their families. Despite this, there are few evidence-based data to guide clinical care. <b>Methods:</b> An NIH-funded, randomized, controlled trial of paroxetine CR, nortriptyline, and placebo in 52 patients with PD and depression. The primary outcomes were the change in the Hamilton Depression Rating Scale (HAM-D) and the percentage of depression responders at 8 weeks. <b>Results:</b> Nortriptyline was superior to placebo for the change in HAM-D (<i>p</i> < 0.002); paroxetine CR was not. There was a trend for superiority of nortriptyline over paroxetine CR at 8 weeks (<i>p</i> < 0.079). Response rates favored nortriptyline (<i>p</i> = 0.024): nortriptyline 53%, paroxetine CR 11%, placebo 24%. In planned contrasts of response rates, nortriptyline was superior to paroxetine CR (<i>p</i> = 0.034). Nortriptyline was also superior to placebo in many of the secondary outcomes, including sleep, anxiety, and social functioning, while paroxetine CR was not. Both active drug treatments were well tolerated. <b>Conclusions:</b> Though relatively modest in size, this is the largest placebo-controlled trial done to date in patients with Parkinson disease (PD) and depression. Nortriptyline was efficacious in the treatment of depression and paroxetine CR was not. When compared directly, nortriptyline produced significantly more responders than did paroxetine CR. The trial suggests that depression in patients with PD is responsive to treatment and raises questions about the relative efficacy of dual reuptake inhibitors and selective serotonin reuptake inhibitors. <b>ARR</b> = absolute risk reduction; <b><i>DSM-IV</i></b> = <i>Diagnostic and Statistical Manual of Mental Disorders,</i> 4th edition; <b>HAM-A</b> = Hamilton Anxiety Scale; <b>HAM-D</b> = Hamilton Depression Rating Scale; <b>MMSE</b> = Mini-Mental State Examination; <b>NNT</b> = number needed to treat; <b>PD</b> = Parkinson disease; <b>PDQ</b> = Parkinson’s Disease Questionnaire; <b>PSQI</b> = Pittsburgh Sleep Quality Index; <b>SCID</b> = Structured Clinical Interview; <b>SSRI</b> = selective serotonin reuptake inhibitor; <b>TCA</b> = tricyclic antidepressant; <b>UPDRS</b> = Unified Parkinson’s Disease Rating Scale.
Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.
La notice
- Revue
- Neurology
- Thématique
- Parkinson's Disease Mechanisms and Treatments
- Domaine
- Medicine
- Établissements canadiens
- —
- Organismes subventionnaires
- National Institutes of HealthNational Institute of Neurological Disorders and StrokeNational Institute of Mental HealthValeant Pharmaceuticals InternationalSanofiGlaxoSmithKlinePfizerNational Institute on Alcohol Abuse and AlcoholismAllerganEli Lilly and CompanyBristol-Myers Squibb
- Mots-clés
- NortriptylineParoxetinePlaceboDepression (economics)Internal medicineMedicinePsychiatryPsychologyAnxietyAntidepressantAmitriptylineAlternative medicine
- Résumé présent dans OpenAlex
- oui